References
- Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535–1548.
- Carroll W, Bhojwani D, Min D, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003:102–131.
- Pui CH, Raimondi SC, Hancock ML, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19)(q23;p13) or its derivative. J Clin Oncol 1994;12:2601–2606.
- Crist WM, Carroll AJ, Slmster JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group Study. Blood 1990;76:117–122.
- Secker-Walker LM, Berger R, Fenaux P, et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992;6:363–369.
- Uckun F, Sensel M, Sather H, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998;16: 527–535.
- Burmeister T, Gökbuget N, Schwartz S, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010;95:241–246.
- Borowitz MJ, Chan JKC. Precursor lymphoid neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissuesIn: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, editors. Lyon, France: IARC2008. pp 167–178.
- Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783–1786.
- Shaffer LG, Slovak ML, Campbell LJ. ISCN (2009): an international system for human cytogenetic nomenclature. Basel: S. Karger2009.
- van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901–1928.
- Sackmann-Muriel F, Felice M, Zubizarreta P, et al. Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM'90 protocol: lack of improvement in high-risk group. Leuk Res 1999;23:331–340.
- Felice MS, Rossi J, Gallego MS, et al. Evolución en el tratamiento de la leucemia linfoblástica aguda en el Hospital de Pediatría Prof. Dr. Juan P. Garrahan. Med Infant 2007;14:92–100.
- Pieters R, Schrappe M, De Lorenzo P, et al. Outcome of infants less than one year of age with acute lymphoblastic leukemia treated with the Interfant-99 protocol. Lancet 2007;370:240–250.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1995;53:457–481.
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II Analysis and examples. Br J Cancer 1997;35:1–39.
- Tarone RE, Wara J. On distribution-free tests for equality of survival distributions. Biometrika 1997;64:156–160.
- Raimondi SC, Behm FG, Roberson PK, et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990;8:1380–1388.
- Pui CH, Campana D, Pei D, et al. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 2009;360:2730–2741.
- Jeha S, Pei D, Raimondi S, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009;23:1406–1409.